Skip to main content
Ocumension Therapeutics logo

Ocumension Therapeutics — Investor Relations & Filings

Ticker · 1477 ISIN · KYG674111011 LEI · 5493000USURI3SIL4Z85 HKEX Manufacturing
Open in API
Filings indexed 460 across all filing types
Latest filing 2023-03-30 Remuneration Information
Country KY Cayman Islands
Listing HKEX 1477

About Ocumension Therapeutics

http://www.ocumension.com

Ocumension Therapeutics is an ophthalmic pharmaceutical platform company dedicated to the research, development, and commercialization of first-in-class or best-in-class therapeutics. The company focuses on providing comprehensive treatment solutions for Chinese patients suffering from ocular diseases. Ocumension has established a complete ophthalmic drug product line, currently holding 20 drug assets covering both anterior and posterior segments of the eye. Its portfolio addresses major conditions such as chronic non-infectious uveitis, infective and allergic conjunctivitis, and diabetic macular edema. The company employs a strategy combining continuous scientific innovation, independent R&D, and strategic alliances to sustain the supply of innovative products across the ophthalmology field.

Recent filings

Filing Released Lang Actions
TERMS OF REFERENCE OF THE REMUNERATION COMMITTEE
Remuneration Information Classification · 95% confidence The document is titled 'TERMS OF REFERENCE OF THE REMUNERATION COMMITTEE' and details the purpose, composition, meetings, authority, and responsibilities of the remuneration committee of Ocumension Therapeutics. It focuses on the committee's role in determining remuneration policies for directors and senior management, referencing compliance with the Listing Rules and Corporate Governance Code. There are no financial statements, earnings data, or report publication announcements. The content is clearly about remuneration governance and committee procedures, fitting the definition of a Remuneration Information report.
2023-03-30 English
PROPOSED AMENDMENTS TO THE EXISTING MEMORANDUM AND ARTICLES OF ASSOCIATION AND ADOPTION OF THE SIXTH MEMORANDUM AND ARTICLES OF ASSOCIATION
Regulatory Filings Classification · 95% confidence The document is an announcement by the company regarding proposed amendments to its memorandum and articles of association, which are subject to shareholder approval at the forthcoming AGM. It references compliance with Listing Rules and the need for shareholder resolution. The document is relatively short (2753 characters) and does not contain actual financial data or detailed report content. It is an announcement about governance changes and upcoming shareholder meeting materials, not the governance report itself or the AGM materials. Therefore, it fits best as a Regulatory Filing (RNS) since it is a formal regulatory announcement that does not fit other specific categories like Governance Information (CGR) or Proxy Solicitation (PSI).
2023-03-30 English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2022
Annual Report Classification · 95% confidence The document is titled 'ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2022' and contains detailed audited consolidated annual results, including financial highlights, business review, research and development progress, and other comprehensive information about the company's performance over the full fiscal year. It includes comparative figures for the previous year, detailed financial data, and management discussion and analysis. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. The presence of audited financial statements and extensive business and financial analysis aligns with the characteristics of an Annual Report (10-K equivalent). Therefore, the document should be classified as an Annual Report (10-K). FY 2022
2023-03-30 English
DATE OF BOARD MEETING
Regulatory Filings Classification · 95% confidence The document is a notice from the Board of Directors of Ocumension Therapeutics announcing the date of a board meeting scheduled for March 30, 2023. The purpose of the meeting includes considering and approving the annual results for the year ended December 31, 2022, and the recommendation for payment of a final dividend. The document does not contain the actual annual results or financial data but is an announcement about the upcoming board meeting where these results will be considered and published. The document length is short (1440 characters), and it serves as a notification rather than the report itself. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement rather than an Annual Report (10-K) or Earnings Release (ER).
2023-03-20 English
VOLUNTARY ANNOUNCEMENT PATIENT ENROLLMENT COMPLETED IN THE PHASE III CLINICAL TRIAL OF OT-702 IN CHINA
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ocumension Therapeutics regarding the completion of patient enrollment in a Phase III clinical trial for a drug (OT-702). It provides business updates about the clinical trial progress and collaboration agreements but does not contain financial data, regulatory filings, or detailed financial reports. The document is relatively short (3719 characters) and serves as a business update announcement rather than a formal financial or regulatory report. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is also not related to capital changes, management changes, or voting results. The content is a voluntary business update announcement about clinical trial progress, which is best classified under Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2023-03-13 English
VOLUNTARY ANNOUNCEMENT INITIATION OF THE PHASE II CLINICAL TRIAL OF OT-202
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ocumension Therapeutics regarding the initiation of a Phase II clinical trial for a drug candidate OT-202. It is an update on business progress and clinical development, not a financial report or regulatory filing. The document is relatively short (2768 characters) and serves as a business update to shareholders and investors. It does not contain financial statements, voting results, management changes, or other regulatory disclosures. It is not an Annual Report, Interim Report, Earnings Release, or any other detailed financial or governance document. It is a voluntary business update announcement, which fits best under the category of Regulatory Filings (RNS) as a general regulatory announcement and business update that does not fit other specific categories.
2023-03-02 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.